Evaluating pharmacogenetic tests: a case example.
Work in human genetics is revealing genes that affect the safe and effective use of pharmaceuticals. Primary care physicians are already receiving advertisements for tests for these variations that emphasize the value of learning about their patients' susceptibility to adverse reactions in order to avoid them. We propose a strategy for the critical evaluation of such offers to ensure the optimal use of these tests.
Department of Pediatrics, the Center for Genetics and Health Policy, Vanderbilt University Medical School, Nashville, TN 37209, USA. carol.freund@vanderbilt.edu
Carol L
CL
Freund
David F
DF
Gregory
Ellen Wright
EW
Clayton
D000329:Advertising; D000617:Aminoglycosides / Q000009:adverse effects; D000900:Anti-Bacterial Agents; D002648:Child; D005194:Family Practice; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D034381:Hearing Loss / Q000139:chemically induced; D006801:Humans; D010597:Pharmacogenetics; D012313:RNA / Q000235:genetics; D000077278:RNA, Mitochondrial
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000077278:RNA, Mitochondrial; D012313:RNA